Drugs / MAGE-A10
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00112242 | Feb 2004 → Mar 2013 | melanoma | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 1 | NCT00112216 | May 1999 → Jun 2007 | melanoma | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mage-A10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00112216 ↗ |
| Modality | Peptide | “Mage-A10 peptide” NCT00112216 ↗ |
| Route | Other | “The peptides are mixed with the adjuvant SB AS-2 or Montanide and injected in a lower limb not affected by the disease” NCT00112216 ↗ |